BLENREP (belantamab mafodotin) - Multiple myeloma

Reason for request

Clinical Benefit

Insufficient

The Committee deems that the clinical benefit of BLENREP (belantamab mafodotin) 100 mg, powder for solution for dilution for infusion, is insufficient in the MA indication to justify public funding.

Clinical Added Value

Not applicable